HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Non-Current Deffered Revenue (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Non-Current Deffered Revenue came in at $10.6 million in Q2 2026, down 65.64% year-over-year from $30.8 million in Q2 2025, and down 47.46% quarter-over-quarter from $20.1 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Non-Current Deffered Revenue for 11 consecutive years, with $10.6 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Non-Current Deffered Revenue fell 65.64% year-over-year to $10.6 million in Q2 2026; TTM through Jun 2026 was $10.6 million, a 65.64% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue was $10.6 million for Q2 2026 at HUTCHMED (China), down from $20.1 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $97.2 million in Q2 2023 and troughed at $190000.0 in Q4 2022.
  • A 5-year average of $36.6 million and a median of $25.5 million in 2025 frame the typical range for Non-Current Deffered Revenue.
  • Across the five-year window, Non-Current Deffered Revenue tumbled 37.61% in 2024 and tumbled 65.64% in 2026, its largest moves.
  • Over 5 years, Non-Current Deffered Revenue stood at $190000.0 in 2022, then surged by 51045.26% to $97.2 million in 2023, then tumbled by 37.61% to $60.6 million in 2024, then sank by 66.79% to $20.1 million in 2025, then slumped by 47.46% to $10.6 million in 2026.
  • The last three Non-Current Deffered Revenue figures came in at $10.6 million (Q2 2026), $20.1 million (Q4 2025), and $30.8 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Amgen 211.50 Bn 197.51 Bn 7.24 Bn -
2 Gilead Sciences 181.29 Bn 178.11 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.55 Bn 74.56 Bn 3.93 Bn 220.40 Mn
5 Argenx Se 61.65 Bn 56.47 Bn 1.37 Bn -
6 Moderna 54.65 Bn 49.52 Bn 52.00 Mn 147.00 Mn
7 Alnylam Pharmaceuticals 34.18 Bn 30.87 Bn 992.69 Mn -
8 Biogen 31.36 Bn 30.07 Bn 1.96 Bn -
9 Roivant Sciences 30.01 Bn 30.01 Bn 1.16 Mn -
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 10.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.58 Mn
Dec 31, 2025 20.13 Mn
Jun 30, 2025 30.79 Mn
Jun 30, 2024 60.63 Mn
Jun 30, 2023 97.18 Mn
Dec 31, 2022 190,000.00
Dec 31, 2020 484,000.00
Dec 31, 2019 133,000.00
Dec 31, 2018 408,000.00
Jun 30, 2018 924,000.00
Dec 31, 2017 1.99 Mn
Dec 31, 2016 2.26 Mn
Dec 31, 2015 2.13 Mn